Skip to main content
search
All Posts By

Rajesh Krishna and David Gutstein

Rajesh Krishna, PhD is a Senior Director in Integrated Drug Development at Certara Strategic Consulting. Rajesh came to Certara after a rich 20+ years of pharmaceutical industry experience in translational and clinical development at Merck, Sanofi (legacy Aventis), and Bristol-Myers Squibb. He has contributed to 40+ INDs, more than 200 Phase 1/1b studies; and to the worldwide registration of 9 new molecular entities. -- David Gutstein, MD is a vice president at Regeneron with keen interest and specialization in gene-based therapeutics and is a guest contributor to this blog. Dr Gutstein’s research includes the Regeneron collaboration with Intellia in gene editing focusing on NTLA-2001 and other programs.